Dr. Jonathan Fromm is a distinguished researcher in hematopathology and clinical laboratory medicine, with a strong focus on flow cytometry, lymphoma biology, and immunophenotypic characterization of hematologic malignancies. His work has significantly advanced diagnostic precision and understanding of diseases such as classical Hodgkin lymphoma, non-Hodgkin lymphomas, and leukemias. With 97 peer-reviewed publications and 5647 citations, his research demonstrates substantial impact, reflected in an h-index of 32. He has contributed extensively to the development of flow cytometric methodologies for disease detection, minimal residual disease assessment, and therapeutic targeting. His research also integrates molecular diagnostics, immunology, and clinical trials, particularly in evaluating biomarkers and targeted therapies. In addition, his contributions to WHO classification chapters and leading journals highlight his role in shaping contemporary hematopathology practices and translational cancer research.